SOHO Highlights: State of the Art and Next Questions

 

SOHO Highlights: State of the Art and Next Questions
D

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Short-Course ABVD w/o RT Based on Negative Interim PET/CT?

By SOHO Highlights: State of the Art and Next Questions FEATURING David Straus
By SOHO Highlights: State of the Art and Next Questions FEATURING David Straus
13 views
February 23, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
2021
14:40
SOHO Highlights: State of the Art and Next Questions

Newly Diagnosed ALCL/PTCL State of the Art: How Can We Improve Outco…

Feat. K. Savage
13:36
SOHO Highlights: State of the Art and Next Questions

SOHO Updates on 1L FL: Does RT+/-(R)CVP Improve PFS in Limited Stage…

Feat. R. Marcus
14:42
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Non-Bulky cHL: Can We Treat Early Disease With Sh…

Feat. D. Straus
09:24
SOHO Highlights: State of the Art and Next Questions

ECHELON-1 Data on Brentuximab Vedotin for Frontline Advanced cHL: Ex…

Feat. D. Straus
10:47
SOHO Highlights: State of the Art and Next Questions

Surveying the Induction and Maintenance Therapy Landscape in Newly D…

Feat. S. Lonial
20:52
SOHO Highlights: State of the Art and Next Questions

MM State of the Art: Approaches to Smoldering, MRD as a Prognostic M…

Feat. S. Lonial
29:37
SOHO Highlights: State of the Art and Next Questions

CML State of the Art: Dasatinib/Imatinib Dose Optimization, STAMPi A…

Feat. M. Deininger
34:50
SOHO Highlights: State of the Art and Next Questions

MPNs State of the Art: What Is the Response to Ruxolitinib vs. BAT? …

Feat. S. Verstovsek
27:43
SOHO Highlights: State of the Art and Next Questions

MDS State of the Art: Imetelstat/Roxadustat for Anemia, Oral HMAs, A…

Feat. G. Garcia-Manero
11:39
SOHO Highlights: State of the Art and Next Questions

Early Stage cHL Management: Bulky vs. Non-bulky Disease, Better Chem…

Feat. D. Straus
14:25
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on Untreated MCL: How Does Deferred Therapy Work? Wh…

Feat. J. Cohen
19:43
SOHO Highlights: State of the Art and Next Questions

SOHO Highlights on R/R MCL: The Role of BTKis, CAR-T, and Chemothera…

Feat. J. Cohen
20:07
SOHO Highlights: State of the Art and Next Questions

R/R PTCL State of the Art: Allo-SCT vs. Auto-SCT? Can Pralatrexate C…

Feat. K. Savage
18:07
SOHO Highlights: State of the Art and Next Questions

SOHO Updates on 1L MZL: Can RT Help in Early Stage MALToma? Is R-Ben…

Feat. R. Marcus
34:46
SOHO Highlights: State of the Art and Next Questions

DLBCL State of the Art: Does Gene Expression Help With the Disease? …

Feat. S. Dave
24:38
SOHO Highlights: State of the Art and Next Questions

Dana-Farber CLL State of the Art: A Review of BTK Inhibitors Data in…

Feat. J. Brown
24:52
SOHO Highlights: State of the Art and Next Questions

CAR-T State of the Art: What Therapies Will Be Available in the Next…

Feat. S. Giralt
29:51
SOHO Highlights: State of the Art and Next Questions

AML State of the Art: Older Patients Management, MRD, Total Oral Com…

Feat. A. Zeidan
29:28
SOHO Highlights: State of the Art and Next Questions

ALL State of the Art at MD Anderson: Hyper-CVAD Combinations, MiniHC…

Feat. H. Kantarjian